Results 121 to 130 of about 187,458 (237)

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

Клиническая онкогематология, 2019
Despite advances in chemo-immunotherapy of chronic lymphocytic leukemia, a choice of therapy is a frequent challenge in patients with a refractory form of the disease, autoimmune hemolytic complications, and also in high-risk patients with cytogenetic ...
Nadezhda Viktorovna Kurkina, E. A. Repina, N. N. Mashnina   +2 more
doaj   +1 more source

T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, Richard Rosenquist, C. I. Edvard Smith, Anders Österborg, Marzia Palma   +13 more
wiley   +1 more source

The X Factor in Immunity: Sex Differences Shaped by the X Chromosome

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT There are sex differences with immune responses where females exhibit stronger immune responses compared to males. Both sex hormones and sex chromosome differences between males and females contribute to the observed sex differences with innate and adaptive immune cell composition and function.
Katherine B. Radovanovic, Megan Wynalda, Montserrat C. Anguera   +2 more
wiley   +1 more source

Ibrutinib for B cell malignancies [PDF]

, 2014
Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies.
Aileen Novero, Delong Liu, George Dous, Pavan M Ravella, Yamei Chen   +4 more
core   +1 more source

Polymethoxylated N‐Carboranyl Isoquinolinones: A New Scaffold for ABCG2 Inhibitors

ChemMedChem, Volume 21, Issue 3, 12 February 2026.
Combinations of a boron‐based clusters (carborane) and polymethoxy group patterns are crucial to overcome ABCG2‐mediated multidrug resistance in cancer cells. (Created in BioRender. Kuhnert, L. (2025) https://BioRender.com/h4cnh5m). ABCG2‐mediated multidrug resistance (MDR) is a major challenge among chemotherapeutic treatments of colon, pancreatic ...
Lydia Kuhnert, Philipp Stockmann, Peter Lönnecke, Mara Anna Wolniewicz, Evamarie Hey‐Hawkins, Walther Honscha   +5 more
wiley   +1 more source

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber   +4 more
doaj   +1 more source

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib [PDF]

, 2015
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy.
FIORCARI, STEFANIA, LUPPI, Mario, MAFFEI, Rossana, MARASCA, Roberto, MARTINELLI, Silvia, POTENZA, Leonardo   +5 more
core   +1 more source

Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease

Journal of Neuroimmune Pharmacology, 2019
Bruton’s tyrosine kinase (BTK), a critical component of B cell receptor signaling, has recently been implicated in regulation of the peripheral innate immune response. However, the role of BTK in microglia, the resident innate immune cells of the central
J. Keaney, Julien Gasser, Gaëlle Gillet, D. Scholz, Irena Kadiu   +4 more
semanticscholar   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis

JCI Insight, 2020
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum.
Johann E. Gudjonsson, Lam C. Tsoi, Feiyang Ma, Allison C. Billi, K.R. van Straalen, A.R.J.V. Vossen, H.H. van der Zee, Paul W. Harms, Rachael Wasikowski, Christine M. Yee, Syed M. Rizvi, Xianying Xing, Enze Xing, Olesya Plazyo, Chang Zeng, Matthew T. Patrick, Margaret M. Lowe, Richard E. Burney, Jeffrey H. Kozlow, Jill R. Cherry-Bukowiec, Yanyun Jiang, Joseph Kirma, Stephan Weidinger, Kelly C. Cushing, Michael D. Rosenblum, Celine Berthier, Amanda S. MacLeod, John J. Voorhees, Fei Wen, J. Michelle Kahlenberg, Emanual Maverakis, Robert L. Modlin, Errol P. Prens   +32 more
doaj   +1 more source